11th Sep 2013 12:38
LONDON (Alliance News) - Oxford BioMedica PLC Wednesday said that it has been awarded GBP7.1 million pounds in government funding to develop a center for making gene-based therapies.
The biopharmaceutical company was the leader of a consortium that won GBP7.7 million in total funding, of which GBP7.1 million was awarded to Oxford BioMedica.
The other members of the consortium were the Heart of England NHS Foundation, Cranfield University, Cell Therapy Catapult Ltd and Biotec Services International Limited.
The project win follows Oxford BioMedica's recently announced collaboration with Novartis to manufacture clinical grade material, utilising the LentiVector gene delivery technology.
Oxford BioMedica shares were up 29%, or 0.6 pence, at 2.70 pence per share Wednesday.
By Rowena Harris-Doughty; [email protected]; @rharrisdoughty
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica